REAL LIFE DATA OF CHRONIC MYELOID LEUKEMIA PATIENTS IN ISPARTA

Murat Ardoğan; Demircan Özbalcı; Emine Güçhan Alanoğlu

Makale detayları

REAL LIFE DATA OF CHRONIC MYELOID LEUKEMIA PATIENTS IN ISPARTA

Yazarlar:

Murat Ardoğan | Demircan Özbalcı | Emine Güçhan Alanoğlu

Yayıncı:

Süleyman Demirel University

Ana Başlıklar:

Clinical Sciences

Dergi:

Medical Journal of Süleyman Demirel University Vol.30 Issue 4, pp.602-609

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001307503

pISSN:

1300-7416

Anahtar kelimeler:

Özet:

 Objective Chronic myeloid leukemia is a myeloproliferative neoplasm with an incidence of 12 cases per 100 000 adults. Central to the pathogenesis of CML, is the fusion of the Abelson murine leukemia ABL1 gene on chromosome 9 with the breakpoint cluster region BCR gene on chromosome 22. The therapeutic landscape changed dramatically with the development of the tyrosine kinase inhibitors TKIs. This targeted approach altered the natural history of CML, improving the 10-year survival rate to 80-90. This study aims to investigate the effective management of TKI treatment and overall survival in real-life CML patients and to discuss the results with current literature. Material and Method Fifty-eight patients who were diagnosed as CML between 2000 and 2018 in Suleyman Demirel University Hematology Department were evaluated. Patients clinical and laboratory characteristics, clinical and demographical features, treatment options, side effects and responses were evaluated in this study. Risk assessment and staging applied with World Health Organization criteria and Sokal Hasford and Eutos risk scoring system. We determined hematological, cytogenetic and molecular response according to European Leukemia Network criteria. Results The average age, male  female ratio and survival rates were found similar to those in literature. The age distribution p  0,001 and Charlson comorbidity index p  0.005 and Charlson comorbidity-age index p  0,000 had a statistically significant effect on overall survival. Age distribution p  0,029, Charlson comorbidity age index p  0,001 and major molecular response at 12 months p  0,028 were found to have a significant effect on disease-free survival. Major molecular response at 12 months p  0,006 also had a statistically significant effect on progression-free survival. Reticular fiber grade did not significantly affect overall survival, disease-free survival and progressionfree survival of patients. Conclusion These results suggest that CML is generally well managed with existing treatment options and that death occur more frequently due to other medical problems. In CML, Charlson indices have been shown to be significantly associated with overall survival and disease-free survival.

 Objective Chronic myeloid leukemia is a myeloproliferative neoplasm with an incidence of 12 cases per 100 000 adults. Central to the pathogenesis of CML, is the fusion of the Abelson murine leukemia ABL1 gene on chromosome 9 with the breakpoint cluster region BCR gene on chromosome 22. The therapeutic landscape changed dramatically with the development of the tyrosine kinase inhibitors TKIs. This targeted approach altered the natural history of CML, improving the 10-year survival rate to 80-90. This study aims to investigate the effective management of TKI treatment and overall survival in real-life CML patients and to discuss the results with current literature. Material and Method Fifty-eight patients who were diagnosed as CML between 2000 and 2018 in Suleyman Demirel University Hematology Department were evaluated. Patients clinical and laboratory characteristics, clinical and demographical features, treatment options, side effects and responses were evaluated in this study. Risk assessment and staging applied with World Health Organization criteria and Sokal Hasford and Eutos risk scoring system. We determined hematological, cytogenetic and molecular response according to European Leukemia Network criteria. Results The average age, male  female ratio and survival rates were found similar to those in literature. The age distribution p  0,001 and Charlson comorbidity index p  0.005 and Charlson comorbidity-age index p  0,000 had a statistically significant effect on overall survival. Age distribution p  0,029, Charlson comorbidity age index p  0,001 and major molecular response at 12 months p  0,028 were found to have a significant effect on disease-free survival. Major molecular response at 12 months p  0,006 also had a statistically significant effect on progression-free survival. Reticular fiber grade did not significantly affect overall survival, disease-free survival and progressionfree survival of patients. Conclusion These results suggest that CML is generally well managed with existing treatment options and that death occur more frequently due to other medical problems. In CML, Charlson indices have been shown to be significantly associated with overall survival and disease-free survival.

 Objective Chronic myeloid leukemia is a myeloproliferative neoplasm with an incidence of 12 cases per 100 000 adults. Central to the pathogenesis of CML, is the fusion of the Abelson murine leukemia ABL1 gene on chromosome 9 with the breakpoint cluster region BCR gene on chromosome 22. The therapeutic landscape changed dramatically with the development of the tyrosine kinase inhibitors TKIs. This targeted approach altered the natural history of CML, improving the 10-year survival rate to 80-90. This study aims to investigate the effective management of TKI treatment and overall survival in real-life CML patients and to discuss the results with current literature. Material and Method Fifty-eight patients who were diagnosed as CML between 2000 and 2018 in Suleyman Demirel University Hematology Department were evaluated. Patients clinical and laboratory characteristics, clinical and demographical features, treatment options, side effects and responses were evaluated in this study. Risk assessment and staging applied with World Health Organization criteria and Sokal Hasford and Eutos risk scoring system. We determined hematological, cytogenetic and molecular response according to European Leukemia Network criteria. Results The average age, male  female ratio and survival rates were found similar to those in literature. The age distribution p  0,001 and Charlson comorbidity index p  0.005 and Charlson comorbidity-age index p  0,000 had a statistically significant effect on overall survival. Age distribution p  0,029, Charlson comorbidity age index p  0,001 and major molecular response at 12 months p  0,028 were found to have a significant effect on disease-free survival. Major molecular response at 12 months p  0,006 also had a statistically significant effect on progression-free survival. Reticular fiber grade did not significantly affect overall survival, disease-free survival and progressionfree survival of patients. Conclusion These results suggest that CML is generally well managed with existing treatment options and that death occur more frequently due to other medical problems. In CML, Charlson indices have been shown to be significantly associated with overall survival and disease-free survival.

 Amaç Kronik myeloid lösemi KML, 100.000 yetişkinde 1-2 vaka insidansı olan myeloproliferatif bir neoplazmdır. KML nin patogenezinin merkezi, kromozom 9 üzerindeki Abelson murin lösemi ABL1 geni ile, kromozom 22 üzerindeki kırılma noktası bölgesi BCR geninin füzyonudur. KML tedavisi, tirozin kinaz inhibitörlerinin TKİ bulunması ile değişmiştir. Bu hedeflenmiş yaklaşım, KML nin doğal seyrini değiştirmiş ve 10 yıllık sağ kalım oranını yaklaşık 80-90lara çıkarmıştır. TKİ ile tedavi altında olan gerçek hayat KML hastalarımızda etkin tedavi yönetiminin yapılıp yapılmadığı, tedavi yanıt oranları ve sağ kalım verilerinin güncel literatür ile benzer olup olmadığının araştırılması amaçlanmıştır. Gereç ve Yöntem Süleyman Demirel Üniversitesi Tıp Fakültesi Hematoloji Bilim Dalında 2000-2018 yılları arasında KML tanısı alan 58 KML hastası çalışmaya alınmıştır. Bu çalışmada hastaların klinik, laboratuvar ve demografik özellikleri, tedavi seçenekleri, yan etkileri ve yanıtları değerlendirildi. Sokal, Hasford ve Eutos risk puanlama sistemi ve Dünya Sağlık Örgütü kriterleri ile risk değerlendirmesi ve evrelemesi uygulandı. European Leukemia Networkün kriterlerine göre hematolojik, sitogenetik ve moleküler yanıtı belirledik. Bulgular Çalışmamızda literatürle benzer yaş ortalaması, erkek kadın oranı saptandı. Çalışmamızda yaş dağılımının p0,001 Charlson komorbidite İndeksi nin p0,005 ve Charlson komorbidite-yaş İndeksi nin p0,000 genel sağkalıma istatistiksel olarak anlamlı etki ettiği görülmüştür. Çalışmamızda yaş dağılımının p  0.029, Charlson komorbidite yaş İndeksi p  0,001 ve 12. ayda Major Moleküler Yanıt MMY alınmasının p  0,028 hastalıksız sağkalıma istatistiksel olarak anlamlı etki ettiği görülmüştür. Çalışmamızda sadece 12. Ayda MMY p0,006 progresyonsuz sağkalıma istatistiksel olarak anlamlı etki ettiği görülmüştür. Hastalarda retiküler lif derecesinin genel sağkalım, hastalıksız sağkalım ve progresyonsuz sağkalıma önemli ölçüde etki etmediği saptanmıştır. Sonuç Bu sonuçlar, KMLnin genellikle mevcut tedavilerle iyi yönetildiğini ve ölümlerin diğer tıbbi problemler nedeniyle daha sık meydana geldiğini göstermektedir. KMLde, Charlson indekslerinin genel sağ kalım ve hastalıksız sağ kalımla anlamlı derecede ilişkili olduğu gösterilmiştir.

Makale detayları

REAL LIFE DATA OF CHRONIC MYELOID LEUKEMIA PATIENTS IN ISPARTA

Yazarlar:

Murat Ardoğan | Demircan Özbalcı | Emine Güçhan Alanoğlu

Yayıncı:

Süleyman Demirel University

Ana Başlıklar:

Clinical Sciences

Dergi:

Medical Journal of Süleyman Demirel University Vol.30 Issue 4, pp.602-609

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001307503

pISSN:

1300-7416

Charlson comorbidity index

Charlson comorbidity-age index

Chronic Myeloid Leukemia

Real life data

PrognosisCharlson komorbidite indeksi

Charlson komorbidite-yaş indeksi

Gerçek yaşam verileri

Kronik Myeloid Lösemi

Prognoz

Sayı

Makale detayları

Yazarlar: Murat Ardoğan | Demircan Özbalcı | Emine Güçhan Alanoğlu

Yayıncı: Süleyman Demirel University

Ana Başlıklar: Clinical Sciences

Dergi: Medical Journal of Süleyman Demirel University Vol.30 Issue 4, pp.602-609

Belge Tipi: Makale

Yayın Tarihi: 12/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001307503

pISSN: 1300-7416

Sayı

Yazarlar:

Murat Ardoğan | Demircan Özbalcı | Emine Güçhan Alanoğlu

Yayıncı:

Süleyman Demirel University

Ana Başlıklar:

Clinical Sciences

Dergi:

Medical Journal of Süleyman Demirel University Vol.30 Issue 4, pp.602-609

Belge Tipi:

Makale

Yayın Tarihi:

12/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001307503

pISSN:

1300-7416